Nanexa

19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?

daemningen4500

Not Invested

Community Contributor

Published

03 Jun 25

daemningen4500's Fair Value

SEK 1.30

58.5% overvalued

23 Jun

SEK 2.06

32.9%

-0.5%

32.9%

-0.5%

You can edit this narrative until Jun 3 7:15 AM. Then, changes will post as Updates.

Author's Valuation

SEK 1.358.5% overvalued

daemningen4500's Fair Value

Narrative

Updates0

daemningen4500'sFair Value

SEK 1.3

58.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.59%

Calculation

SEK 20.07m

Earnings '30

27.83x

PE Ratio '30

SEK 558.68m

Market Cap '30

SEK 558.68m

Market Cap '30

324.37m

No. shares '30

SEK 1.72

Share Price '30

SEK 1.72 Share Price '30

Discounted to 2025 @ 5.86% p.a.

SEK 1.30

Fair Value '25